Current state of type 1 diabetes treatment in the U.S.

updated data from the T1D Exchange clinic registry

T1D Exchange Clinic Network

Research output: Contribution to journalArticle

448 Citations (Scopus)

Abstract

To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from 75 years. The overall average HbA1c was 8.2% (66 mmol/mol) at enrollment and 8.4% (68 mmol/mol) at the most recent update. During childhood, mean HbA1c decreased from 8.3% (67 mmol/mol) in 2-4-year-olds to 8.1% (65 mmol/mol) at 7 years of age, followed by an increase to 9.2% (77 mmol/mol) in 19-year-olds. Subsequently, mean HbA1c values decline gradually until ∼30 years of age, plateauing at 7.5-7.8% (58-62 mmol/mol) beyond age 30 until a modest drop in HbA1c below 7.5% (58 mmol/mol) in those 65 years of age. Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain all too common complications of treatment, especially in older (SH) and younger patients (DKA). Insulin pump use increased slightly from enrollment (58-62%), and use of continuous glucose monitoring (CGM) did not change (7%). Although the T1D Exchange registry findings are not population based and could be biased, it is clear that there remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups. Barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)971-978
Number of pages8
JournalDiabetes Care
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Registries
Hemoglobins
Diabetic Ketoacidosis
Hypoglycemia
Therapeutics
Age Groups
Insulin
Technology
Glucose
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current state of type 1 diabetes treatment in the U.S. updated data from the T1D Exchange clinic registry. / T1D Exchange Clinic Network.

In: Diabetes Care, Vol. 38, No. 6, 01.06.2015, p. 971-978.

Research output: Contribution to journalArticle

@article{bbc4bba1f4b64a109cf339ba3a58eafd,
title = "Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry",
abstract = "To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from 75 years. The overall average HbA1c was 8.2{\%} (66 mmol/mol) at enrollment and 8.4{\%} (68 mmol/mol) at the most recent update. During childhood, mean HbA1c decreased from 8.3{\%} (67 mmol/mol) in 2-4-year-olds to 8.1{\%} (65 mmol/mol) at 7 years of age, followed by an increase to 9.2{\%} (77 mmol/mol) in 19-year-olds. Subsequently, mean HbA1c values decline gradually until ∼30 years of age, plateauing at 7.5-7.8{\%} (58-62 mmol/mol) beyond age 30 until a modest drop in HbA1c below 7.5{\%} (58 mmol/mol) in those 65 years of age. Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain all too common complications of treatment, especially in older (SH) and younger patients (DKA). Insulin pump use increased slightly from enrollment (58-62{\%}), and use of continuous glucose monitoring (CGM) did not change (7{\%}). Although the T1D Exchange registry findings are not population based and could be biased, it is clear that there remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups. Barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 diabetes.",
author = "{T1D Exchange Clinic Network} and Miller, {Kellee M.} and Foster, {Nicole C.} and Beck, {Roy W.} and Bergenstal, {Richard M.} and DuBose, {Stephanie N.} and Linda DiMeglio and Maahs, {David M.} and Tamborlane, {William V.}",
year = "2015",
month = "6",
day = "1",
doi = "10.2337/dc15-0078",
language = "English (US)",
volume = "38",
pages = "971--978",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Current state of type 1 diabetes treatment in the U.S.

T2 - updated data from the T1D Exchange clinic registry

AU - T1D Exchange Clinic Network

AU - Miller, Kellee M.

AU - Foster, Nicole C.

AU - Beck, Roy W.

AU - Bergenstal, Richard M.

AU - DuBose, Stephanie N.

AU - DiMeglio, Linda

AU - Maahs, David M.

AU - Tamborlane, William V.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from 75 years. The overall average HbA1c was 8.2% (66 mmol/mol) at enrollment and 8.4% (68 mmol/mol) at the most recent update. During childhood, mean HbA1c decreased from 8.3% (67 mmol/mol) in 2-4-year-olds to 8.1% (65 mmol/mol) at 7 years of age, followed by an increase to 9.2% (77 mmol/mol) in 19-year-olds. Subsequently, mean HbA1c values decline gradually until ∼30 years of age, plateauing at 7.5-7.8% (58-62 mmol/mol) beyond age 30 until a modest drop in HbA1c below 7.5% (58 mmol/mol) in those 65 years of age. Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain all too common complications of treatment, especially in older (SH) and younger patients (DKA). Insulin pump use increased slightly from enrollment (58-62%), and use of continuous glucose monitoring (CGM) did not change (7%). Although the T1D Exchange registry findings are not population based and could be biased, it is clear that there remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups. Barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 diabetes.

AB - To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from 75 years. The overall average HbA1c was 8.2% (66 mmol/mol) at enrollment and 8.4% (68 mmol/mol) at the most recent update. During childhood, mean HbA1c decreased from 8.3% (67 mmol/mol) in 2-4-year-olds to 8.1% (65 mmol/mol) at 7 years of age, followed by an increase to 9.2% (77 mmol/mol) in 19-year-olds. Subsequently, mean HbA1c values decline gradually until ∼30 years of age, plateauing at 7.5-7.8% (58-62 mmol/mol) beyond age 30 until a modest drop in HbA1c below 7.5% (58 mmol/mol) in those 65 years of age. Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain all too common complications of treatment, especially in older (SH) and younger patients (DKA). Insulin pump use increased slightly from enrollment (58-62%), and use of continuous glucose monitoring (CGM) did not change (7%). Although the T1D Exchange registry findings are not population based and could be biased, it is clear that there remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups. Barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84942755473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942755473&partnerID=8YFLogxK

U2 - 10.2337/dc15-0078

DO - 10.2337/dc15-0078

M3 - Article

VL - 38

SP - 971

EP - 978

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -